Mechanism of acute antibody-mediated rejection in ABO-incompatible kidney transplantation: Which anti-A/anti-B antibodies are responsible, natural or de novo?

Transplantation

Volumn 89, Issue 5, 2010, Pages 635-637

  Takahashi, Kota ^a   Saito, Kazuhide ^a   Nakagawa, Yuki ^a   Tasaki, Masayuki ^a   Hara, Noboru ^a   Imai, Naofumi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; BLOOD GROUP A ANTIBODY; BLOOD GROUP B ANTIBODY; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ACUTE GRAFT REJECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; BLOOD GROUP ABO SYSTEM; CAPILLARY; CLINICAL ARTICLE; FLOW CYTOMETRY; GRAFT FAILURE; HISTOCOMPATIBILITY; HUMAN; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LETTER; PRIORITY JOURNAL; SPLENECTOMY; SURVIVAL RATE;

ABO BLOOD-GROUP SYSTEM; BIOPSY; BLOOD GROUP ANTIGENS; BLOOD GROUP INCOMPATIBILITY; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION;

EID: 77949392093     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c89307     Document Type: Letter

References (10)

1. Takahashi K, Saito K, Takahara S, et al; Japanese ABO-Incompatible Kidney Transplantation Committee. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4: 1089.
2. Takahashi K, Tanabe K, Ota K,et al. Prophylactic use of new immunosuppressive agent, deoxyspergualin, in patients with kidney transplantation from ABO-incompatible or preformed antibody positive donors. Transplant Proc 1991; 23: 1078.
3. Takahashi K. ABO-incompatible kidney transplantation\Establishing a scientific framework. Amsterdam, Elsevier 2007.
4. Saito K, Nakagawa Y, Takahashi K, et al. Pinpoint targeted immunosuppression: Anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xeno-transplant 2006; 13: 111.
5. Imai N, Nishi S, Takahashi K, et al. Immu-nohistochemical evidence of activated lectin pathway in kidney allografts with peritubu-lar capillary C4d deposition. Nephrol Dial Transplant 2006; 21: 2589.
6. Tasaki M, Yoshida Y, Takahashi K, et al. Identification and characterization of major proteins carrying ABO blood group antigens in human kidney. Transplantation 2009; 87: 1125.
7. Rydberg L, Breimer ME, Pascher I, et al. Characterization of the anti-A antibody response following an ABO incompatible (A2 to O) kidney transplantation. Mol Immunol 1992; 29: 547.
8. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusion, splenectomy, and double-filtration plasmapheresis. Transplantation 2002; 74: 1207.
9. Tyden G, Kumlien G, Fehrman I. Successful ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Transplantation 2003; 76: 730.
10. Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: A paradigm ready for broad implementation. Transplantation 2009; 87: 1246.